|
1
|
Loehrer PJ and Einhorn LH: Drugs five
years later. Cisplatin Ann Intern Med. 100:704–713. 1984.PubMed/NCBI
|
|
2
|
Perilongo G, Maibach R, Shafford E, et al:
Cisplatin versus cisplatin plus doxorubicin for standard-risk
hepatoblastoma. N Engl J Med. 361:1662–1670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pritchard J, Brown J, Shafford E, et al:
Cisplatin, doxorubicin, and delayed surgery for childhood
hepatoblastoma: a successful approach - results of the first
prospective study of the International Society of Pediatric
Oncology. J Clin Oncol. 18:3819–3828. 2000.
|
|
4
|
Sullivan MJ: Hepatoblastoma, cisplatin,
and ototoxicity: good news on deaf ears. Cancer. 115:5623–5626.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ortega JA, Douglass EC, Feusner JH, et al:
Randomized comparison of cisplatin/vincristine/fluorouracil and
cisplatin/continuous infusion doxorubicin for treatment of
pediatric hepatoblastoma: A report from the Children’s Cancer Group
and the Pediatric Oncology Group. J Clin Oncol. 18:2665–2675.
2000.PubMed/NCBI
|
|
6
|
Perilongo G, Shafford E, Maibach R, et al:
Risk-adapted treatment for childhood hepatoblastoma. Final report
of the second study of the International Society of Paediatric
Oncology - SIOPEL 2. Eur J Cancer. 40:411–421. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zsiros J, Maibach R, Shafford E, et al:
Successful treatment of childhood high-risk hepatoblastoma with
dose-intensive multiagent chemotherapy and surgery: final results
of the SIOPEL-3HR study. J Clin Oncol. 28:2584–2590. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cvitkovic E: Cumulative toxicities from
cisplatin therapy and current cytoprotective measures. Cancer Treat
Rev. 24:265–281. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Knight KR, Kraemer DF and Neuwelt EA:
Ototoxicity in children receiving platinum chemotherapy:
underestimating a commonly occurring toxicity that may influence
academic and social development. J Clin Oncol. 23:8588–8596. 2005.
View Article : Google Scholar
|
|
10
|
Chonghaile TN and Letai A: Mimicking the
BH3 domain to kill cancer cells. Oncogene. 27(Suppl 1): 149–157.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lieber J, Kirchner B, Eicher C, et al:
Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in
hepatoblastoma cells. Pediatr Blood Cancer. 55:1089–1095. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adesina AM, Lopez-Terrada D, Wong KK, et
al: Gene expression profiling reveals signatures characterizing
histologic subtypes of hepatoblastoma and global deregulation in
cell growth and survival pathways. Hum Pathol. 40:843–853. 2009.
View Article : Google Scholar
|
|
13
|
Konopleva M, Contractor R, Tsao T, et al:
Mechanisms of apoptosis sensitivity and resistance to the BH3
mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lieber J, Eicher C, Wenz J, et al: The BH3
mimetic ABT-737 increases treatment efficiency of paclitaxel
against hepatoblastoma. BMC Cancer. 11:3622011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lieber J, Ellerkamp V, Wenz J, et al:
Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.
Pediatr Surg Int. 28:149–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oltersdorf T, Elmore SW, Shoemaker AR, et
al: An inhibitor of Bcl-2 family proteins induces regression of
solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trudel S, Stewart AK, Li Z, et al: The
Bcl-2 family protein inhibitor, ABT-737, has substantial
antimyeloma activity and shows synergistic effect with
dexamethasone and melphalan. Clin Cancer Res. 13:621–629. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Delft MF, Wei AH, Mason KD, et al: The
BH3 mimetic ABT-737 targets selective Bcl-2 proteins and
efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Cancer Cell. 10:389–399. 2006.PubMed/NCBI
|
|
19
|
High LM, Szymanska B, Wilczynska-Kalak U,
et al: The Bcl-2 homology domain 3 mimetic ABT-737 targets the
apoptotic machinery in acute lymphoblastic leukemia resulting in
synergistic in vitro and in vivo interactions with established
drugs. Mol Pharmacol. 77:483–494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mason KD, Khaw SL, Rayeroux KC, et al: The
BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic
chemotherapy agents in chronic lymphocytic leukemia. Leukemia.
23:2034–2041. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cairo S, Armengol C, De Reynies A, et al:
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and
Myc signaling in aggressive childhood liver cancer. Cancer Cell.
14:471–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Doi I: Establishment of a cell line and
its clonal sublines from a patient with hepatoblastoma. Gann.
67:1–10. 1976.PubMed/NCBI
|
|
23
|
Pietsch T, Fonatsch C, Albrecht S, Maschek
H, Wolf HK and von Schweinitz D: Characterization of the continuous
cell line HepT1 derived from a human hepatoblastoma. Lab Invest.
74:809–818. 1996.PubMed/NCBI
|
|
24
|
Warmann SW, Heitmann H, Teichmann B, et
al: Effects of P-glycoprotein modulation on the chemotherapy of
xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol.
22:373–386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reynolds M: Conversion of unresectable to
resectable hepatoblastoma and long-term follow-up study. World J
Surg. 19:814–816. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haberle B, Bode U and von Schweinitz D:
Differentiated treatment protocols for high- and standard-risk
hepatoblastoma - an interim report of the German Liver Tumor Study
HB99. Klin Padiatr. 215:159–165. 2003.(In German).
|
|
27
|
von Schweinitz D, Byrd DJ, Hecker H, et
al: Efficiency and toxicity of ifosfamide, cisplatin and
doxorubicin in the treatment of childhood hepatoblastoma. Study
Committee of the Cooperative Paediatric Liver Tumour Study HB89 of
the German Society for Paediatric Oncology and Haematology. Eur J
Cancer. 33:1243–1249. 1997.
|
|
28
|
Roux PP and Blenis J: ERK and p38
MAPK-activated protein kinases: a family of protein kinases with
diverse biological functions. Microbiol Mol Biol Rev. 68:320–344.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Warmann SW, Frank H, Heitmann H, et al:
Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg
Res. 144:43–48. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ono K and Han J: The p38 signal
transduction pathway: activation and function. Cell Signal.
12:1–13. 2000. View Article : Google Scholar
|
|
31
|
Chauhan D, Velankar M, Brahmandam M, et
al: A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in
multiple myeloma. Oncogene. 26:2374–2380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warmann S, Hunger M, Teichmann B, Flemming
P, Gratz KF and Fuchs J: The role of the MDR1 gene in the
development of multidrug resistance in human hepatoblastoma:
clinical course and in vivo model. Cancer. 95:1795–1801. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tse C, Shoemaker AR, Adickes J, et al:
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hwang JJ, Kuruvilla J, Mendelson D, et al:
Phase I dose finding studies of obatoclax (GX15-070), a small
molecule pan-BCL-2 family antagonist, in patients with advanced
solid tumors or lymphoma. Clin Cancer Res. 16:4038–4045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Paik PK, Rudin CM, Brown A, et al: A phase
I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan
in solid tumor malignancies. Cancer Chemother Pharmacol.
66:1079–1085. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schimmer AD, O’Brien S, Kantarjian H, et
al: A phase I study of the pan bcl-2 family inhibitor obatoclax
mesylate in patients with advanced hematologic malignancies. Clin
Cancer Res. 14:8295–8301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mason KD, Carpinelli MR, Fletcher JI, et
al: Programmed anuclear cell death delimits platelet life span.
Cell. 128:1173–1186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang H, Nimmer PM, Tahir SK, et al: Bcl-2
family proteins are essential for platelet survival. Cell Death
Differ. 14:943–951. 2007.PubMed/NCBI
|
